Search research articles
Contact Us
Filters
Showing results (111-120 of 122) with videos related to
Page
of 13
Sort By:
Journal of Hematology & Oncology
|
January 25, 2025
Correction: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
Dirk Hose, Seemun Ray, Sina Rößler, et al.
Haematologica
|
December 7, 2014
The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells
Niels Weinhold, Tobias Meissner, David C Johnson, et al.
Leukemia
|
July 21, 2020
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
Elias K Mai, Kaya Miah, Uta Bertsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 12, 2025
Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials
Qian Shi, Bruno Paiva, Levi D Pederson, et al.
Leukemia
|
November 17, 2021
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
Elias K Mai, Kaya Miah, Uta Bertsch, et al.
Leukemia
|
July 23, 2020
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
Hartmut Goldschmidt, Marc-Andrea Baertsch, Jana Schlenzka, et al.
Cancer Cell
|
March 7, 2017
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment
Anja Seckinger, Jose Antonio Delgado, Samuel Moser, et al.
Leukemia
|
February 9, 2020
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial
Hartmut Goldschmidt, Elias K Mai, Jan Dürig, et al.
Cancers
|
October 13, 2021
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial
Eva-Maria Klein, Diana Tichy, Hans J Salwender, et al.
Blood Cancer Journal
|
January 8, 2021
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Marc-Andrea Baertsch, Elias K Mai, Thomas Hielscher, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 122) with videos related to
Sort By:
Page
of 13
Journal of Hematology & Oncology
|
January 25, 2025
Correction: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
Dirk Hose, Seemun Ray, Sina Rößler, et al.
Haematologica
|
December 7, 2014
The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells
Niels Weinhold, Tobias Meissner, David C Johnson, et al.
Leukemia
|
July 21, 2020
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
Elias K Mai, Kaya Miah, Uta Bertsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 12, 2025
Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials
Qian Shi, Bruno Paiva, Levi D Pederson, et al.
Leukemia
|
November 17, 2021
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
Elias K Mai, Kaya Miah, Uta Bertsch, et al.
Leukemia
|
July 23, 2020
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
Hartmut Goldschmidt, Marc-Andrea Baertsch, Jana Schlenzka, et al.
Cancer Cell
|
March 7, 2017
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment
Anja Seckinger, Jose Antonio Delgado, Samuel Moser, et al.
Leukemia
|
February 9, 2020
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial
Hartmut Goldschmidt, Elias K Mai, Jan Dürig, et al.
Cancers
|
October 13, 2021
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial
Eva-Maria Klein, Diana Tichy, Hans J Salwender, et al.
Blood Cancer Journal
|
January 8, 2021
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Marc-Andrea Baertsch, Elias K Mai, Thomas Hielscher, et al.
Page
of 13